# A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

Source: https://onco.cc/trials/nct07030907/  
OnCo record `nct07030907` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of OPB-101 run by Outpace Bio, Inc., terminated.

## Summary

A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer is a phase 1 interventional study registered as NCT07030907 by Outpace Bio, Inc., with 3 participants enrolled, started 2025-06-16. Conditions recorded: Ovarian Cancer Recurrent, Ovarian Cancer and Platinum Resistant Ovarian Cancer. Interventions recorded: OPB-101.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07030907
- Phase: 1
- Setting: A Phase 1a/b Study to Evaluate the Safety and Efficacy of OPB-101, an Autologous Mesothelin (MSLN) CAR T Cell Therapy With Antigen-dependent Expression of OUTSMART™ Designed IL-2 Cytokine in Platinum-resistant Ovarian Cancer
- Sponsor: Outpace Bio, Inc.
- Enrolled: 3

## Sources

- ClinicalTrials.gov NCT07030907: https://clinicaltrials.gov/study/NCT07030907

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Platinum-resistant ovarian cancer](https://onco.cc/cancers/platinum-resistant-ovarian-cancer/)
- drugs: [OPB-101](https://onco.cc/drugs/opb-101/)
- companies: [Outpace Bio](https://onco.cc/companies/outpace-bio/)

---
JSON: https://onco.cc/api/v1/entities/nct07030907.json